Product Description.:
5
Tablet , film-coated , pink , scored , oval oblong
Corlanor? is indicated for1:
◾Patients with stable, symptomatic chronic HF with LVEF ≤ 35% and in sinus rhythm with resting heart rate ≥ 70 bpm
CORLANOR.
CORLANOR (ivabradine) tablets, for oral use
Initial U.S. Approval: 2015
--------------------------- INDICATIONS AND USAGE ----------------------------
Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated
channel blocker indicated to reduce the risk of hospitalization for worsening
heart failure in patients with stable, symptomatic chronic heart failure with left
ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart
rate ≥ 70 beats per minute and either are on maximally tolerated doses of betablockers
or have a contraindication to beta-blocker use. (1)
----------------------- DOSAGE AND ADMINISTRATION -----------------------
Starting dose is 5 mg twice daily. After 2 weeks of treatment, adjust dose
based on heart rate. The maximum dose is 7.5 mg twice daily. (2)
In patients with conduction defects or in whom bradycardia could lead to
hemodynamic compromise, initiate dosing at 2.5 mg twice daily. (2)
--------------------- DOSAGE FORMS AND STRENGTHS ----------------------
Tablets: 5 mg, 7.5 mg (3)
------------------------------ CONTRAINDICATIONS ------------------------------
Acute decompensated heart failure (4)
Blood pressure less than 90/50 mmHg (4)
Sick sinus syndrome, sinoatrial block or 3rd degree AV block, unless a
functioning demand pacemaker is present (4)
Resting heart rate less than 60 bpm prior to treatment (4)
Severe hepatic impairment (4)
Pacemaker dependence (heart rate maintained exclusively by the
pacemaker) (4)
